NASHVILLE, TN — Cannabidiol (CBD) administration is associated with a significant reduction in seizure frequency in patients with drug-resistant pediatric epilepsy, according to data published in the journal Epilepsy & Behavior.
Vanderbilt University researchers retrospectively assessed the impact of the adjunctive use of grey-market CBD products in a cohort of 108 children with refractory epilepsy.
Authors reported: “The addition of CBD resulted in 39 percent of patients having a greater than 50 percent reduction in seizures, with 10 percent becoming seizure-free. … No patients achieved CBD monotherapy, although the weaning of other antiepileptic drugs became possible in 22 percent of patients. … Increased alertness and improved verbal interactions were reported in 14 percent of patients in the CBD group.”
They concluded: “These data add additional support for the use of artisanal CBD in the treatment of drug-resistant epilepsy. … [O]utside of seizure control, CBD use was also associated with increased alertness, improved verbal communication, better social interactions, and better mood, suggesting additional benefits to use of CBD. … In summary, these findings support efficacy of artisanal CBD preparations in seizure reduction with few significant side effects.”
Later this year, regulators at the US Food and Drug Administration will undertake a ‘priority review’ of this data to determine whether to grant Epidiolex market approval.
Full text of the study, “Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences of a tertiary medical center,” appear in Epilepsy & Behavior.